RT期刊文章SR电子T1和路易体痴呆:病理基础的扣带岛标志(P6.332)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP P6.332 VO 82是10补充A1乔纳森Graff-Radford A1梅丽莎·首页默里A1 Val劳A1布拉德利Boeve A1坦尼斯Ferman A1斯科特Przybelski A1 (Timothy Lesnick A1马修Senjem A1杰弗里Gunter A1格伦·史密斯A1 David Knopman A1 Clifford杰克A1丹尼斯·迪克森A1罗纳德·彼得森A1 Kejal Kantarci年2014 UL //www.ez-admanager.com/content/82/10_Supplement/P6.332.abstract AB目的:探讨临床、成像和病理协会的扣带岛(CIS)和路易体痴呆迹象(下文)。背景:临床诊断下文仍然不佳,尽管改善临床标准。抽出后扣带相对于楔片和楔前叶(CIS),已被建议作为[18 f] 2-fluoro-deoxy-D-glucose (FDG) PET生物标记区分下文与阿尔茨海默病(AD),但这个标志的病理基础是不清楚。设计/方法:我们回顾性确定连续病例的临床诊断下文(n = 39)和匹配广告(n = 39)和患者认知正常受试者(n = 78)接受FDG和11 c-pittsburgh化合物b(加以)PET扫描。我们研究的病人尸检(n = 10)和接受Braak-neurofibrillary混乱(非功能性测试)阶段。结果:受试者的临床诊断下文亦有明显高于CIS FDG PET相比,广告主题(p < 0.001),独立存在的β-amyloid负载加以宠物(p = 0.66)。尸检确诊病例,6/8的患者临床诊断下文的中间或高可能性下文病理学和积极的CIS FDG PET的视觉评估。2/8与临床下文但负面CIS AD病理诊断。CIS是消极的广告在两个患者临床诊断,证实了尸检。更高的CIS与较低的Braak-NFT阶段(r = -0.92; p<0.001). CONCLUSIONS: Our study finds that the presence of the CIS on FDG PET is not associated with β-amyloid load, but indicates a lower Braak-NFT stage in patients with DLB. Patients with a positive CIS fit into the high or intermediate probability DLB pathology group and are clinically diagnosed with DLB not AD. Identifying biomarkers which can measure relative contributions of underlying pathologies to a patient’s dementia is critical as neurotherapeutics moves towards targeted treatments. Study Supported by: AG040042/AG11378/AG16574/AG06786/Mangurian FoundationDisclosure: Dr. Graff-Radford has nothing to disclose. Dr. Murray has nothing to disclose. Dr. Lowe has received personal compensation for activities with Bayer Pharmaceuticals Corp. Dr. Lowe has received research support from GE Health Care, Siemens Molecular Imaging, and AVID Radiopharmaceuticals, Inc. Dr. Boeve has received research support from Cephalon, Inc., Allon Therapeutics, and GE Healthcare. Dr. Ferman has nothing to disclose. Dr. Przybelski has nothing to disclose. Dr. Lesnick has received personal compensation for activities with Reproductive Medicine and Infertility Associates as a consultant. Dr. Senjem has nothing to disclose. Dr. Gunter has nothing to disclose. Dr. Smith has nothing to disclose. Dr. Knopman has received personal compensation for activities with Eli Lilly & Company and TauRx Pharmaceuticals. Dr. Knopman has received personal compensation in an editorial capacity for Neurology. Dr. Knopman has received research support from Janssen and Baxter. Dr. Jack has received personal compensation for activities with Janssen, Eisai Inc., General Electric, Johnson & Johnson, and Eli Lilly & Co. Dr. Jack has received research support from Pfizer Inc., Allon, and Baxter. Dr. Dickson has received personal compensation for activities with Neotope, Inc. as a consultant. Dr. Petersen has received personal compensation for activities with Pfizer, Inc., and Janssen Alzheimer's Immunotherapy. Dr. Petersen has received royalty payments from Oxford University Press. Dr. Kantarci has received research support from Pfizer Inc., Jannsen Alzheimer immunotherapy, and Takeda Global Research & Development Center.Thursday, May 1 2014, 7:30 am-11:00 am